Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923318 | 0.89 | CYP2A13 (0.63) | KDM4EALDH1A1SIGMAR1CYP2A13 | |
| SCHEMBL2926469 | 0.85 | ALDH1A1 (0.50) | KDM4EALDH1A1POLBSIGMAR1 | |
| SCHEMBL24508364 | 0.76 | KDM4E (0.73) | KDM4EALDH1A1POLBTDP1SIGMAR1 | |
| SCHEMBL30596611 | 0.75 | KDM4E (0.71) | KDM4EALDH1A1POLBTDP1SIGMAR1 | |
| SCHEMBL2927630 | 0.75 | KDM4E (0.52) | KDM4EALDH1A1POLBTDP1MEN1 | |
| SCHEMBL2931423 | 0.74 | PDE4B (0.50) | ALDH1A1SIGMAR1CYP2A13MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL2930007 | 0.73 | SIGMAR1 (0.57) | KDM4EALDH1A1POLBTDP1SIGMAR1 | |
| SCHEMBL2928148 | 0.73 | APP (0.54) | MEN1KMT2A | |
| SCHEMBL8276926 | 0.73 | SLC6A2 (0.49) | MAPTOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL8278910 | 0.73 | SLC6A2 (0.49) | MAPTOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | KDM4E 315/4885ALDH1A1 4027/4885POLB 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.